 Comparison MU interferon placebo patients chronic non-A non-B hepatitis Ninety patients chronic non-A non-B hepatitis SC injections placebo MU recombinant interferon times weeks Complete normalization alanine aminotransferase levels posttreatment patients MU MU untreated patients MU Alanine aminotransferase normalization months therapy patients MU MU placebo decline alanine aminotransferase levels interferon therapy independent positive correlations female sex age Knodell fibrosis score age MU interferon effective dose MU disease activity non-A non-B chronic hepatitis patients Women noncirrhotic patients likely